TXNIP and obesity due to melanocortin 4 receptor deficiency: These observations make TXNIP a promising therapeutic target for obesity and diabetes type I and type II treatment [15], especially since it has been previously shown that mice devoid of TXNIP, despite having an increased fat mass, are indeed protected from developing insulin resistance [155], and that TXNIP depletion protects mice against β cell apoptosis [119].